Abstract
A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.
| Original language | English |
|---|---|
| Pages (from-to) | 116-121 |
| Number of pages | 6 |
| Journal | Annals of Medicine |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 1 2015 |
Fingerprint
Keywords
- Cancer
- Low-molecular-weight heparin
- Prophylaxis
- Survival
- Therapy
- Venous thromboembolism
ASJC Scopus subject areas
- Medicine(all)
Cite this
Low-molecular-weight heparins and cancer : Focus on antitumoral effect. / Franchini, Massimo; Mannucci, Pier Mannuccio.
In: Annals of Medicine, Vol. 47, No. 2, 01.03.2015, p. 116-121.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low-molecular-weight heparins and cancer
T2 - Focus on antitumoral effect
AU - Franchini, Massimo
AU - Mannucci, Pier Mannuccio
PY - 2015/3/1
Y1 - 2015/3/1
N2 - A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.
AB - A close relationship between cancer and thrombosis does exist, documented by the fact that an overall 7-fold increased risk of venous thromboembolism (VTE) has been reported in patients with malignancy compared to non-malignancy. The potential impact of antithrombotic agents in cancer-associated VTE has long been recognized, and, in particular, several clinical trials in the last 20 years have reported the safety and efficacy of low-molecular-weight heparins (LMWHs) for treatment and prophylaxis of VTE in patients with various types of cancer. More recently, a number of preclinical and clinical studies have suggested that LMWHs may improve survival in cancer patients with mechanisms that are different from its antithrombotic effect but are linked to the ability of influencing directly the tumor biology. This paper reviews the evidence around the potential survival benefits of LMWHs by analyzing the suggested mechanisms and the available clinical data.
KW - Cancer
KW - Low-molecular-weight heparin
KW - Prophylaxis
KW - Survival
KW - Therapy
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84928103842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928103842&partnerID=8YFLogxK
U2 - 10.3109/07853890.2015.1004361
DO - 10.3109/07853890.2015.1004361
M3 - Article
C2 - 25766973
AN - SCOPUS:84928103842
VL - 47
SP - 116
EP - 121
JO - Annals of Medicine
JF - Annals of Medicine
SN - 0785-3890
IS - 2
ER -